25/11/2020 - Institutional news
The Hospital del Mar Medical Research Institute (IMIM) and the Josep Carreras Leukaemia Research Institute (IJC) have signed a collaboration agreement with the aim of jointly promoting scientific research, teaching and training personnel in the healthcare field, as well as pooling their efforts to efficiently manage public and/or private resources available for biomedical research activities in the field of haematology-oncology.
Més informació "Strategic alliance with the Josep Carreras Foundation for research into haematology"
23/11/2020 - Institutional news
The BAPP (Bioanalysis, Proteomics and Pharmacology), a collaborative centre from the Hospital del Mar Medical Research Institute (IMIM) and the UPF, has obtained the TECNIO accreditation for the period 2020-2023. This seal, which the centre had already obtained in previous editions, is awarded by the Government of Catalonia through ACCIÓN. It identifies and raises the profile of centres with high scientific and technical capacities that are considered to be developers of differential technologies and which are leaders when it comes to transferring their knowledge and technologies to industry. The BAPP is a multidisciplinary centre specialising in research and service activities in four sectors: pharmacology, neurosciences, peptide chemistry, and bioanalysis. Its main focus is the development of new drugs for human and veterinary use. It comprises the Integrated Pharmacology and Systems Neuroscience (Farmacologia Integrada i Neurociència de Sistemes; FINS) research group of the IMIM-Hospital del Mar, on the one hand, and the Proteomics and Protein Chemistry research group from the UPF on the other.
18/11/2020 - Institutional news
Jordi Alonso, director of the Epidemiology and Public Health Programme, Montse Fitó, coordinator of the Cardiovascular Risk and Nutrition research group, Joaquim Bellmunt, a researcher in the Cancer Molecular Therapy research group and Margarita Triguero-Mas, researcher in the Healthy cities and environmental justice (UAB-IMIM) appear on the list of the world's most cited scientists published by Clarivate Analytics, a company that provides services in research, patents and other areas related to innovation. This annual list identifies researchers who have displayed significant influence in their chosen research field(s) through the publication of numerous highly cited articles over the past decade. Their names are drawn from publications that are in the top 1% for citations by field and year of publication in the Web of Science citation index.
18/08/2020 - Institutional news
Dra. Jana Selent, coordinator of the GPCR drug discovery group, has been selected as the featured author of the month for the August edition in the journal Nature Methods. Recently, the Group of Dra. Selent published his latest article GPCRmd uncovers the dynamics of the 3D-GPCRome in this journal, where she presents a new tool to study one of the key elements in cell signaling, G protein-coupled receptors (GPCRs) which are the target of almost 40% of current drugs. This tool, the GPCRmd platform, will help improve our understanding of the function of these receptors, which are critical for transmitting signals to the interior of cells. The design of this tool has been made possible thanks to a consortium of researchers from 23 different institutions of 10 different European countries and the United States, led by the group of Dr. Jana Selent and with important contributions from researchers of the Paul Scherrer Institute (PSI) in Switzerland and the Autonomous University of Barcelona.
Més informació "Nature Methods selects Jana Selent as the featured author of the month for August"
24/07/2020 - Institutional news
In the first edition of the Responsible Research and Innovation (RRI) in Health Awards organised by ISCIII and promoted as part of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge) three proposals from three different Health Research Institutes (HRI) have been honoured out of a total of 26 proposals received. One of these three proposals is an IMIM project: The name of the successful project is "Co-creation and citizen participation in the design of the PENSA Study on the Prevention of Cognitive Impairment in People with Subjective Memory Complaints". Presented by Natàlia Soldevila and Laura Forcano from the Integrated Pharmacology and Systems Neuroscience research group at the IMIM, this work stands out for its application of citizen participation in the design of a clinical trial, an added value that allows the project to be reoriented to better adapt to the needs and expectations of the participants.
23/04/2020 - Institutional news
The Scientific Advisory Board (SAB) is made up of a group of prestigious international scientists, experts in the different areas corresponding to the IMIM research programs. Until very recently the president of the SAB was Dr. Joaquin Arribas, but with his incorporation as director of the IMIM and scientific director of the PSMAR, will take his place Dr. Xosé R. Bustelo, Deputy Director of the Cancer Research Center (CIC), University of Salamanca-CSIC, Director of the Genomics and Proteomics Unit and coordinator of the Tumor Progression Mechanisms Program at the same center. He is also a member of the CIBERONC Steering Committee. Dr. Bustelo holds a PhD in Biology from the University of Santiago de Compostela, his scientific training includes several stays at international research centers such as the Bristol Myers Squibb Pharmaceutical Research Institute (Princeton, New Jersey, USA), as a postdoctoral fellow and later as Research Scientist and in the Department of Pathology at State University of New York (Stony Brook, New York, USA, as an Assistant Professor.
Més informació "New chairman of the IMIM External Scientific Advisory Board"
The IMIM Clinical Metabolomics Platform led by Dr. Oscar J. Pozo, from the IMIM Integrated Pharmacology and Systems Neuroscience Research Group, has become part of the EATRIS consortium, the European infrastructure for translational medicine, as part of the biomarker platform. This means that the IMIM is now part of a consortium comprising more than 80 prestigious European institutes that is aiming to establish synergies between healthcare researchers by providing them with the most advanced technologies and the experience needed to make headway in translational medicine. EATRIS is a European Research Infrastructure Consortium (ERIC) whose main objective is to advance translational medicine. Translational research is a highly multidisciplinary and complex undertaking. One of the greatest challenges in innovation is to understand which steps are necessary and the most appropriate technology and knowledge for taking these steps.
19/03/2020 - Institutional news
The IMIM Foundation announces one position for a Recognised Researcher (R4) with the objective of incorporating into the Institute a researcher of excellence, a leader of research in his/her field, and of international prestige in the field of Biomedicine. The incorporation of the candidate should add significant value to the Institute and make a notable contribution towards achieving the Institute's strategic objectives. Researchers from competitive programmes, such as the Ramón y Cajal and similar programmes, who have made exceptional contributions, will be considered. The candidate must have a PhD in the field of Biomedicine and an exceptional research career, with an excellent leadership capacity and proven international experience in one of the IMIM Foundation's research programmes: Cancer, Epidemiology and Public Health, Inflammatory and Cardiovascular Disorders, Biomedical Informatics, or Neurosciences.
Més informació "Call for one position for Recognised Researcher (R4)"
17/03/2020 - Institutional news
Following the state of alarm declared throughout Spain due to COVID-19 and the recommendations of the Catalan authorities to collaborate in preventing the spread of COVID-19, from Monday March 16th onwards, the IMIM staff will be teleworking and will be able to assist you via email and/or telephone. If you have any doubts or questions, you can contact us through the general form on the website: https://www.imim.es/en_contacte.html or by writing to the email addresses of the research areas and groups that are listed on that website.
20/01/2020 - Institutional news
Joaquín Arribas is an ICREA Research Professor at the Vall d'Hebron Institute of Oncology (VHIO) and Scientific Director at CIBERONC. He studied biochemistry at the Universidad Autónoma de Madrid (1987) where he later worked on the regulation of proteasome catalytic activities and got his PhD in Biology (1991). Sponsored by a grant from the Ministry of Education and Science, he joined the Memorial Sloan-Kettering Cancer Center in New York (USA) as a postdoctoral fellow with Joan Massagué (1992-96), where he worked on the proteolytic processing of transmembrane growth factors. In 1997 he joined the Department of Oncological Research at Vall d'Hebron Hospital in Barcelona, since which time he has been directing the Growth Factors group. In 2010, he was appointed director of the VHIO preclinical research programme, and in 2017 he became the scientific director at CIBERONC. His research has been recognised by the EMBO Young Investigator Programme Beckman Coultek Award, given to the best Spanish researcher in Biochemistry and Molecular Biology.
Més informació "Dr. Joaquín Arribas, new PSMAR research director and IMIM director"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
